Sep 6, 2018 Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program
Jun 4, 2018 Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting
May 25, 2018 Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone
